Genentech
Also known as: GENENTECH | Genentech and Biogen IDEC | Genentech, Inc. | GENENTECH INC | Genentech, Inc., University of Colorado Denver, National Jewish, Beth Israel Deaconess Medical Center, and Long Island Jewish Hospital | Genentech/Roche | Genentech (South San Francisco, California, USA) | Genetech
Highest phase reached
Phase 4
First clinical trial
Dec 31, 1992
First marketed drug
Apr 6, 1979First NDA
Oct 17, 1985Last known activity
Jan 31, 2026
Timeline
1970s
- Jan 1, 1976
Genentech— Founded
- Apr 6, 1979
somatropin— NDA Secondary Org
2010s
- Feb 22, 2013
trastuzumab emtansine— NDA Organization
2020s
- Aug 7, 2020
risdiplam— Marketing Organization
Drugs by trial phase (430 distinct, 1479 trials)
Phase 4 (40 own, 1 via acquisition)
Phase 3 (65 own, 0 via acquisition)
Phase 2 (205 own, 2 via acquisition)
Phase 1 (109 own, 1 via acquisition)
Other trials (7 own, 0 via acquisition)
Indications
Approved for
Studied for
- Abdominal Abscess
- Abscess
- Acquired Immunodeficiency Syndrome
- Acute Lung Injury
- Adenocarcinoma
- Adenocarcinoma, Clear Cell
- Adenocarcinoma, Mucinous
- Adenocarcinoma of Lung
- Adenoma, Islet Cell
- Adnexal Diseases
- Adrenocortical Carcinoma
- Aggression
- AIDS-Related Complex
- Airway Obstruction
- Alopecia
- Alopecia Areata
- Alzheimer Disease
- Amyotrophic Lateral Sclerosis
- Angioid Streaks
- Anorexia
- Anorexia Nervosa
- Anthracosis
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Antiphospholipid Syndrome
- Arthritis
- Arthritis, Juvenile
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Ascites
- Asthma
- Astrocytoma
- Atherosclerosis
- Atrophy
- Autoimmune Diseases
- Bacteremia
- Basal Cell Carcinoma
- Basal Cell Nevus Syndrome
- Biliary Tract Neoplasms
- Bone Diseases, Metabolic
- Brain Neoplasms
- Breast Neoplasms
- Brenner Tumor
- Bronchiolitis
- Bronchiolitis Obliterans
- Burkitt Lymphoma
- Carcinoid Tumor
- Carcinoma
- Carcinoma, Endometrioid
- Carcinoma, Hepatocellular
- Carcinoma, Merkel Cell
- Carcinoma, Neuroendocrine
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinoma, Small Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Carcinosarcoma
- Cardiovascular Diseases
- Cataract
- Central Serous Chorioretinopathy
- Cerebral Hemorrhage
- Cholangiocarcinoma
- Cholangitis
- Cholangitis, Sclerosing
- Chondrosarcoma
- Choroidal Neovascularization
- Choroiditis
- Churg-Strauss Syndrome
- Colitis
- Colitis, Ulcerative
- Colorectal Neoplasms
- Communicable Diseases
- Conjunctival Neoplasms
- Corneal Neovascularization
- Coronary Artery Disease
- Coronary Disease
- Coronavirus Infections
- Crohn Disease
- Cystadenocarcinoma
- Cystadenocarcinoma, Serous
- Cystic Fibrosis
- Cytomegalovirus Infections
- Deafness
- Depression
- Dermatitis
- Dermatitis, Atopic
- Dermatomyositis
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Diabetic Foot
- Diabetic Nephropathies
- Diabetic Retinopathy
- Diarrhea
- Digestive System Diseases
- Digestive System Neoplasms
- Disease
- Disease Progression
- Dissociative Disorders
Marketed drugs (33)
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (50)
- NCT04256265Lead sponsorN/A—
- NCT04395508Lead sponsorN/A—
- NCT04395508Study directorN/A—
- NCT00000774CollaboratorPhase 1—
- NCT07059494CollaboratorPhase 4Jan 31, 2026
- NCT07059091CollaboratorPhase 2Jan 31, 2026
- NCT06984341OfficialPhase 1Dec 1, 2025
- NCT06984341Lead sponsorPhase 1Dec 1, 2025
- NCT07052695CollaboratorPhase 1/Phase 2Nov 30, 2025
- NCT07113691CollaboratorPhase 1Nov 30, 2025
- NCT06904911CollaboratorPhase 2Nov 15, 2025
- NCT07214766Lead sponsorPhase 1Oct 17, 2025
- NCT07214766OfficialPhase 1Oct 17, 2025
- NCT07008378OfficialPhase 1Oct 15, 2025
- NCT07008378Lead sponsorPhase 1Oct 15, 2025
Details
- Founded
- South San Francisco, CA, US Jan 1, 1976
- First NDA
- Oct 17, 1985
- Last known activity
- Jan 31, 2026
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy
- Accelerated approval